Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, we have done very, very well |
| In Crohn’s, we saw very, very strong efficacy |
| 400 has tremendous potential |
| When I look at the business, we are in a very strong position to deliver on the high single-digit growth CAGR that we expect for this decade |
| If you look at SKYRIZI and our guidance this year, we expect to grow about $2.7 billion, really very robust growth |
| We’ve actually put more behind R&D, because we are very excited about the programs in our pipeline as we think about the drivers of growth in the next decade, but also continuing to invest in external innovation |
| So as I think about how Cerevel fits with AbbVie and really helping us drive that long-term growth in neuroscience, I think it was a very nice transaction for us |
| I think we’ve performed exceptionally well |
| We also have a very interesting opportunity |
| We obviously increased our long-term guidance expectations for that on the Q4 call, but we’re seeing very nice performance from the asset |
| It certainly has been impressively resilient in 2023 |
| But I think what we would like folks to think about is the very strong data we see in full spectrum bipolar and in adjunctive MDD and the growth we are going to continue to see there |
| And so I think that, that worked very well for us |
| So, I think Jeff and his team done a remarkable job |
| We’re seeing extremely strong in-place share, still around 50% |
| So, we are able to continue to have a very, very strong engine here despite that loss of the frontline access in some of those indications |
| So tremendous growth in Crohn’s, and then we anticipate the UC approval in the middle of this year |
| I would say we’re obviously very pleased with the amount of parity access that we were able to retain this year, which drove some of the upside that you’re referring to |
| So, there is a lot of uptake, and it continues to grow very strongly, I would say |
| And when we look at that one and you see in the naive data, you see very high efficacy and extremely high efficacy in the maintenance data |
| And what we have observed is a very nice tolerability and a very favorable safety profile |
| So, in all the original atopic dermatitis data, the safety profile has been very strong |
| 50% of those patients that progress will have elevations in c-Met and our early data has shown an ORR of 50% and very strong data consistent with the wild type |
| And so the way that we come at the market, particularly given the sequencing that we have to do for RINVOQ is our representatives will be able to highlight really best-in-class efficacy for us [Technical Difficulty], which is clearly in the data |
| And that one has shown very strong efficacy in colorectal cancer |
| So it’s really about driving continued strong execution for AbbVie |
| And plus they are seeing very high benefit and efficacy in particular in inflammatory bowel disease, where similar to atopic dermatitis, that patients are substantially younger than they are in rheumatoid arthritis |
| We executed very well against it with the payer contracting |
| We’re excited about the portfolio we have in place that we’ve assembled over the first 11 years |
| Unidentified Company Representative We’re obviously very excited about the serial transaction |
| Statement |
|---|
| So what that does is puts a little bit pressure on the top line data |
| And another competitor in the ‘23 space has now failed their Crohn’s data head-to-head |
| I would have to say that as the year went on, we did see some more resiliency on volume |
| When we look at how these patients are treated today, the tolerability is very challenging, the compliance is very challenging, especially if you consider if they would have to get a therapy more than once a day |
| You have seen us actually increase that investment over the last couple of years despite the fact that we have seen our earnings decline |
| Jeff Stewart Just to add to Roopal’s point, I think it’s important, which is while it’s very unlikely that you are going to see a change of the sequencing or the loss of frontline that happened with oral surveillance with the JAK class |
| And as you sequence through biologics, or JAK inhibitor efficacy continues to step down |
| And you could be challenged by comparing that data to another trial because one thing that we have seen in Crohn’s is a so-called control arm or placebo arm, was still pretty high in the maintenance data |
| So when we look at that way, there’s always going to be, I think, some resistance in terms of where that volume may come out because it’s small molecule purely interchangeable orange book type AB-rated material |
| We’ve obviously concede price to deliver that |
| They are not seeing that |
| They’re not tolerating |
| And while we will see some of that volume degradation, we still see the majority – the vast majority of the business will remain at a parity position with these biosimilars over the course of 2024 |
| It seems like it’s progressed and I missed that |
| Steve Scala The UC data didn’t look as competitive as we would have liked, given the fact that the maintenance data in biologically experienced patients seem less than that of your competitors |
| That way, cross-trial comparisons are unnecessary |
| What has – and it has surprised us, what has surprised you the most? And maybe, Jeff, this is the best question maybe your best answer |
| We’re also waiting the full pivotal Phase 2 data for telisotuzumab |
| Steve Scala And what are the factors that produce a tail in the first place? We investors have witnessed a lot of massive patent expirations |
| And the reason for that is and what we are told is they are not seeing the adverse events that are in the box warning, whether they are cardiovascular or thromboembolic |
Please consider a small donation if you think this website provides you with relevant information